1-6 of 6
Steven T. Rosen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma

Robert Chen, Alex F. Herrera, Jessie Hou, Lu Chen, Jun Wu, Yuming Guo, Timothy W. Synold, Vu N. Ngo, Sandrine Puverel, Matthew Mei, Leslie Popplewell, Shuhua Yi, Joo Y. Song, Shu Tao, Xiwei Wu, Wing C. Chan, Stephen J. Forman, Larry W. Kwak, Steven T. Rosen, Edward M. Newman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (5): 1034–1044.
https://doi.org/10.1158/1078-0432.CCR-19-1768
Published: 02 March 2020
View article titled, Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma
Open the PDF for Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, Mala Shanmugam
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (5): 1161–1171.
https://doi.org/10.1158/1078-0432.CCR-14-1088
Published: 01 March 2015
View article titled, Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Open the PDF for Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin in another window
Includes: Supplementary data
Journal Articles

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, Youhong Fan, Uma Giri, Praveen K. Tumula, Monique B. Nilsson, Jayanthi Gudikote, Hai Tran, Robert J.G. Cardnell, David J. Bearss, Steven L. Warner, Jason M. Foulks, Steven B. Kanner, Varsha Gandhi, Nancy Krett, Steven T. Rosen, Edward S. Kim, Roy S. Herbst, George R. Blumenschein, J. Jack Lee, Scott M. Lippman, K. Kian Ang, Gordon B. Mills, Waun K. Hong, John N. Weinstein, Ignacio I. Wistuba, Kevin R. Coombes, John D. Minna, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 279–290.
https://doi.org/10.1158/1078-0432.CCR-12-1558
Published: 02 January 2013
View article titled, An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Open the PDF for An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins

Christiane Querfeld, Steven T. Rosen, Joan Guitart, Alfred Rademaker, David S. Pezen, M. Eileen Dolan, Joseph Baron, Daniel B. Yarosh, Francine Foss, Timothy M. Kuzel
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (17): 5748–5754.
https://doi.org/10.1158/1078-0432.CCR-11-0556
Published: 01 September 2011
View article titled, Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with <em>O</em><sup>6</sup>-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins
Open the PDF for Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with <em>O</em><sup>6</sup>-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins in another window
Journal Articles

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

Andrew M. Evens, William G. Spies, Irene B. Helenowski, David Patton, Stewart Spies, Borko D. Jovanovic, Sarah Miyata, Elizabeth Hamilton, Daina Variakojis, Jun Chen, Louie Naumovski, Steven T. Rosen, Jane N. Winter, Richard A. Miller, Leo I. Gordon
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (20): 6462–6471.
https://doi.org/10.1158/1078-0432.CCR-09-0905
Published: 14 October 2009
View article titled, The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [<sup>90</sup>Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial
Open the PDF for The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [<sup>90</sup>Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies

Stephanie Greenstein, Kulsoom Ghias, Nancy L. Krett, Steven T. Rosen
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (6): 1681–1694.
Published: 01 June 2002
View article titled, Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies
Open the PDF for Mechanisms of Glucocorticoid-mediated Apoptosis in Hematological Malignancies in another window